Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Treasury Shares: 2015-2025

Historic Treasury Shares for Cartesian Therapeutics (RNAC) over the last 8 years, with Sep 2025 value amounting to $523,254.

  • Cartesian Therapeutics' Treasury Shares rose 16.74% to $523,254 in Q3 2025 from the same period last year, while for Sep 2025 it was $523,254, marking a year-over-year increase of 16.74%. This contributed to the annual value of $444,238 for FY2024, which is N/A change from last year.
  • As of Q3 2025, Cartesian Therapeutics' Treasury Shares stood at $523,254, which was down 1.89% from $533,331 recorded in Q2 2025.
  • Cartesian Therapeutics' Treasury Shares' 5-year high stood at $2.5 million during Q1 2023, with a 5-year trough of $394,450 in Q4 2021.
  • Moreover, its 3-year median value for Treasury Shares was $528,292 (2025), whereas its average is $1.0 million.
  • In the last 5 years, Cartesian Therapeutics' Treasury Shares skyrocketed by 470.80% in 2021 and then slumped by 81.16% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Treasury Shares (Quarterly) stood at $394,450 in 2021, then skyrocketed by 332.39% to $1.7 million in 2022, then rose by 15.93% to $2.1 million in 2023, then plummeted by 78.17% to $444,238 in 2024, then rose by 16.74% to $523,254 in 2025.
  • Its last three reported values are $523,254 in Q3 2025, $533,331 for Q2 2025, and $572,605 during Q1 2025.